Karyopharm Therapeutics (KPTI) Given a $18.00 Price Target at Cantor Fitzgerald

Cantor Fitzgerald set a $18.00 price objective on Karyopharm Therapeutics (NASDAQ:KPTI) in a research note issued to investors on Wednesday morning. The firm currently has a buy rating on the stock. Cantor Fitzgerald also issued estimates for Karyopharm Therapeutics’ FY2018 earnings at ($3.24) EPS.

“STORM Data. Top-line data from the STORM (Phase IIb) trial in penta- refractory multiple myeloma, which has been granted accelerated approval, are expected in late-April.”,” the firm’s analyst commented.

How to Become a New Pot Stock Millionaire

A number of other brokerages also recently commented on KPTI. Canaccord Genuity upped their target price on shares of Karyopharm Therapeutics from $18.00 to $22.00 and gave the stock a buy rating in a research note on Monday, March 12th. HC Wainwright upped their target price on shares of Karyopharm Therapeutics to $26.00 and gave the stock a buy rating in a research note on Thursday, March 15th. JPMorgan Chase & Co. restated an overweight rating and issued a $19.00 target price (up from $18.00) on shares of Karyopharm Therapeutics in a research note on Friday, March 16th. Robert W. Baird set a $22.00 target price on shares of Karyopharm Therapeutics and gave the stock a buy rating in a research note on Thursday, March 15th. Finally, BidaskClub upgraded shares of Karyopharm Therapeutics from a buy rating to a strong-buy rating in a research note on Thursday, March 8th. Two equities research analysts have rated the stock with a sell rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $19.60.

KPTI stock opened at $13.76 on Wednesday. The company has a market cap of $743.30, a PE ratio of -4.91 and a beta of 3.62. Karyopharm Therapeutics has a one year low of $7.48 and a one year high of $18.00.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, March 15th. The company reported ($0.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.66) by ($0.14). The company had revenue of $1.53 million during the quarter, compared to the consensus estimate of $2.26 million. Karyopharm Therapeutics had a negative return on equity of 89.62% and a negative net margin of 67,267.47%. Karyopharm Therapeutics’s revenue was up 3163.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.65) earnings per share. equities analysts forecast that Karyopharm Therapeutics will post -2.79 EPS for the current year.

In other news, insider Sharon Shacham sold 10,000 shares of the stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $10.08, for a total transaction of $100,800.00. Following the transaction, the insider now directly owns 723,510 shares in the company, valued at $7,292,980.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Mansoor Raza Mirza sold 2,500 shares of the stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $17.01, for a total transaction of $42,525.00. Following the transaction, the director now owns 2,500 shares in the company, valued at $42,525. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 69,000 shares of company stock worth $928,625. Insiders own 14.71% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in KPTI. Northern Trust Corp boosted its stake in Karyopharm Therapeutics by 36.5% in the second quarter. Northern Trust Corp now owns 405,374 shares of the company’s stock valued at $3,668,000 after acquiring an additional 108,369 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Karyopharm Therapeutics by 17.3% in the second quarter. Dimensional Fund Advisors LP now owns 323,671 shares of the company’s stock valued at $2,930,000 after acquiring an additional 47,699 shares in the last quarter. Voya Investment Management LLC boosted its stake in Karyopharm Therapeutics by 42.1% in the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock valued at $136,000 after acquiring an additional 4,444 shares in the last quarter. State Street Corp boosted its stake in Karyopharm Therapeutics by 10.1% in the second quarter. State Street Corp now owns 511,920 shares of the company’s stock valued at $4,631,000 after acquiring an additional 47,127 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Karyopharm Therapeutics by 26.2% in the second quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock valued at $243,000 after acquiring an additional 5,586 shares in the last quarter. Institutional investors own 62.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3297951/karyopharm-therapeutics-kpti-given-a-18-00-price-target-at-cantor-fitzgerald.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

WEC Energy Group  Receives Media Impact Rating of 0.31
WEC Energy Group Receives Media Impact Rating of 0.31
Welltower  Receiving Favorable Press Coverage, Report Shows
Welltower Receiving Favorable Press Coverage, Report Shows
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact IHS Markit  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact IHS Markit Stock Price
Somewhat Favorable News Coverage Somewhat Unlikely to Impact Coca-Cola European Partners  Stock Price
Somewhat Favorable News Coverage Somewhat Unlikely to Impact Coca-Cola European Partners Stock Price
Karmacoin Price Up 16% Over Last 7 Days
Karmacoin Price Up 16% Over Last 7 Days
Compcoin Hits Market Capitalization of $0.00
Compcoin Hits Market Capitalization of $0.00


© 2006-2018 Ticker Report. Google+.